CTI BioPharma Corp. (NASDAQ:CTIC)’s stock has been of interest for both individual investors and Wall Street analysts recently. Let’s look at the crowd and equity research sentiment so that we can get a solid idea as to where the shares might be headed. Should we buy, sell or hold?
Zacks collects broker services based on the information provided by 1 analysts. These services are then Zacks into their five-point ratings scale, allowing for easier interpretation for private investors. This differs from the Crowd Ratings scale, because Zacks numbers work in the opposite direction. Zacks says one is a “Strong Buy” and five is a Strong Sell. CTI BioPharma Corp. (NASDAQ:CTIC)’s ABR (average broker rating) is 3.67.
Street analysts anticipate that the social media giant would post quarterly share earnings of $-0.07. The actual earnings that the firm reported last quarter was $-0.1. Interested parties will be awaiting the moment when CTI BioPharma Corp. (NASDAQ:CTIC) will reveal their actual results on 2017-02-21.
Now let’s look at the Closing Bell. Individual investors can rate a stock according a sliding scale where “one” is a Strong Sell and “five” is a Strong Buy. CTI BioPharma Corp. (NASDAQ:CTIC)’s crowd consensus rating is 2.5. This rating is derived from the 2 ratings provided by individuals investors.
Brokerage Firm Analysts View
Private investors also pay attention to how Wall Street researchers react to stocks. Zacks Research, a well-respected research firm with over 30 years of experience, compiles all of this brokerage data and then produce rankings and predictive data. Wall Street sell-side analysts anticipated that CTI BioPharma Corp. (NASDAQ:CTIC)’s shares will reach a high of $0.75-$0.75. The consensus target is at $0.75.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.